BR112013012697A2 - "method for decreasing expression, production or secretion of an angiogenic factor or hypertrophic factor or both by mesenchymal stem cells, methods for decreasing an inhibitory effect, a deleterious effect, and a mesenchymal stem cell apoptosis effect, a method for increasing a mesenchymal stem cell stimulating effect, composition, and method for preparing cartilage in an individual diagnosed with diseased or damaged cartilage. " - Google Patents

"method for decreasing expression, production or secretion of an angiogenic factor or hypertrophic factor or both by mesenchymal stem cells, methods for decreasing an inhibitory effect, a deleterious effect, and a mesenchymal stem cell apoptosis effect, a method for increasing a mesenchymal stem cell stimulating effect, composition, and method for preparing cartilage in an individual diagnosed with diseased or damaged cartilage. "

Info

Publication number
BR112013012697A2
BR112013012697A2 BR112013012697A BR112013012697A BR112013012697A2 BR 112013012697 A2 BR112013012697 A2 BR 112013012697A2 BR 112013012697 A BR112013012697 A BR 112013012697A BR 112013012697 A BR112013012697 A BR 112013012697A BR 112013012697 A2 BR112013012697 A2 BR 112013012697A2
Authority
BR
Brazil
Prior art keywords
effect
mesenchymal stem
stem cell
decreasing
cartilage
Prior art date
Application number
BR112013012697A
Other languages
Portuguese (pt)
Inventor
Barbara Dale Boyan
Christopher S D Lee
Ramsey C Kinney
Shirae Kerisha Leslie
Zyi Schwartz
Original Assignee
Georgia Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgia Tech Res Inst filed Critical Georgia Tech Res Inst
Publication of BR112013012697A2 publication Critical patent/BR112013012697A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/70—Polysaccharides
    • C12N2533/74—Alginate

Abstract

método para diminuir expressão, produção ou secreção de um fator angiogênico ou fator hipertrófico ou ambos por células-tronco mesenquimais, métodos para diminuir um efeito inibidor, um efeito deletério, e um efeito de apoptose de células-tronco mesenquimais, método para aumentar um efeito estimulador de células-tronco mesenquimais, composição, e, método para preparar cartilagem em um indivíduo diagnosticado com cartilagem doente ou danificada. são divulgados métodos e composições de carreadores de microconta para distribuição de células e outras substâncias biologicamente ativas para tecido doente ou danificado em um indivíduo em necessidade das mesmas.method for decreasing expression, production or secretion of an angiogenic factor or hypertrophic factor or both by mesenchymal stem cells, methods for decreasing an inhibitory effect, a deleterious effect, and a mesenchymal stem cell apoptosis effect, method for enhancing an effect mesenchymal stem cell stimulator, composition, and method for preparing cartilage in an individual diagnosed with diseased or damaged cartilage. Methods and compositions of microcount carriers for delivery of cells and other biologically active substances to diseased or damaged tissue in an individual in need thereof are disclosed.

BR112013012697A 2010-11-23 2011-11-23 "method for decreasing expression, production or secretion of an angiogenic factor or hypertrophic factor or both by mesenchymal stem cells, methods for decreasing an inhibitory effect, a deleterious effect, and a mesenchymal stem cell apoptosis effect, a method for increasing a mesenchymal stem cell stimulating effect, composition, and method for preparing cartilage in an individual diagnosed with diseased or damaged cartilage. " BR112013012697A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41646310P 2010-11-23 2010-11-23
US201061426018P 2010-12-22 2010-12-22
PCT/US2011/062068 WO2012071527A2 (en) 2010-11-23 2011-11-23 Protein delivery from stem cell microcarriers

Publications (1)

Publication Number Publication Date
BR112013012697A2 true BR112013012697A2 (en) 2016-09-06

Family

ID=46146426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013012697A BR112013012697A2 (en) 2010-11-23 2011-11-23 "method for decreasing expression, production or secretion of an angiogenic factor or hypertrophic factor or both by mesenchymal stem cells, methods for decreasing an inhibitory effect, a deleterious effect, and a mesenchymal stem cell apoptosis effect, a method for increasing a mesenchymal stem cell stimulating effect, composition, and method for preparing cartilage in an individual diagnosed with diseased or damaged cartilage. "

Country Status (7)

Country Link
US (1) US10441610B2 (en)
EP (1) EP2643012B1 (en)
BR (1) BR112013012697A2 (en)
CA (1) CA2818894C (en)
CO (1) CO6761392A2 (en)
IL (1) IL226501A (en)
WO (1) WO2012071527A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2643012B1 (en) 2010-11-23 2019-07-10 Georgia Tech Research Corporation Protein delivery from stem cell microcarriers
FR3029790B1 (en) * 2014-12-12 2017-01-13 Synolyne Pharma CHITOSAN HYDROGEL MICROBELL
WO2016112111A1 (en) * 2015-01-08 2016-07-14 The Board Of Trustees Of The Leland Stanford Junior University Factors and cells that provide for induction of bone, bone marrow, and cartilage
US11384328B2 (en) 2015-11-18 2022-07-12 President And Fellows Of Harvard College Cartridge-based system for long term culture of cell clusters
CA3025308A1 (en) * 2016-05-24 2017-11-30 The Regents Of The University Of California Growth-factor nanocapsules with tunable release capability for bone regeneration
CN110114092A (en) * 2016-09-27 2019-08-09 崔东桓 For delivering aqueous bait to control the biodegradable hydrogel of pest ant
US11629318B2 (en) 2017-10-20 2023-04-18 President And Fellows Of Harvard College Methods for producing mature adipocytes and methods of use thereof
US11167375B2 (en) 2018-08-10 2021-11-09 The Research Foundation For The State University Of New York Additive manufacturing processes and additively manufactured products
US20220265831A1 (en) * 2019-08-27 2022-08-25 Crannmed Limited Alginate Based Particles as a Temporary Embolic Agent
US20230002750A1 (en) * 2019-12-04 2023-01-05 Amano Enzyme Inc. Preparation of adipose tissue-derived cell population
US20230405179A1 (en) 2021-03-03 2023-12-21 Crannmed Limited Alginate Based Particles as a Temporary Embolic Agent
CN114767662A (en) * 2022-03-28 2022-07-22 江苏大学 Controlled-release microsphere encapsulating human mesenchymal stem cells and preparation method and storage method thereof
WO2024052780A1 (en) 2022-09-07 2024-03-14 Crannmed Limited Self-degrading enzyme loaded biologically derived particles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849594B1 (en) * 1999-06-30 2005-02-01 John Lawler Purification and use of human recombinant cartilage oligomeric matrix protein
US20050282733A1 (en) * 2002-06-27 2005-12-22 Prins Johannes B Differentiation modulating agents and uses therefor
US7273756B2 (en) * 2004-10-01 2007-09-25 Isto Technologies, Inc. Method for chondrocyte expansion with phenotype retention
US8202701B2 (en) * 2004-10-08 2012-06-19 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
WO2007099337A1 (en) * 2006-03-01 2007-09-07 Cartela R&D Ab Expansion and differentiation of mesenchymal stem cells
US8273373B2 (en) * 2008-12-30 2012-09-25 Case Western Reserve University Photocrosslinked biodegradable hydrogel
US9393267B2 (en) * 2009-02-19 2016-07-19 University Of Southern California Gel delivery system for tissue repair
US20130039990A1 (en) * 2010-04-30 2013-02-14 University Of Maryland, Baltimore Injectable, load-bearing cell/microbead/calcium phosphate bone paste for bone tissue engineering
EP2643012B1 (en) 2010-11-23 2019-07-10 Georgia Tech Research Corporation Protein delivery from stem cell microcarriers

Also Published As

Publication number Publication date
WO2012071527A3 (en) 2012-10-04
CA2818894A1 (en) 2012-05-31
CA2818894C (en) 2019-02-12
EP2643012B1 (en) 2019-07-10
CO6761392A2 (en) 2013-09-30
US10441610B2 (en) 2019-10-15
IL226501A0 (en) 2013-07-31
US20140370111A1 (en) 2014-12-18
IL226501A (en) 2017-10-31
EP2643012A4 (en) 2014-05-14
WO2012071527A2 (en) 2012-05-31
EP2643012A2 (en) 2013-10-02

Similar Documents

Publication Publication Date Title
BR112013012697A2 (en) "method for decreasing expression, production or secretion of an angiogenic factor or hypertrophic factor or both by mesenchymal stem cells, methods for decreasing an inhibitory effect, a deleterious effect, and a mesenchymal stem cell apoptosis effect, a method for increasing a mesenchymal stem cell stimulating effect, composition, and method for preparing cartilage in an individual diagnosed with diseased or damaged cartilage. "
WO2011049414A3 (en) Method for inducing migration of adult stem cells derived from adipose tissue
GB2472964A (en) Vectors for delivery of light-sensitive proteins and methods of use
AR080030A1 (en) TREATMENT OF TYPES OF CANCER OSEO THROUGH THE USE OF PLACENTARY MOTHER CELLS
NZ591293A (en) Methods and compositions for treatment of bone defects with osteogenic placental adherent cells (OPACs)
RU2012105922A (en) DIFFERENTIATION OF HUMAN EMBRYONAL STEM CELLS
MX2013002488A (en) Methods and compositions for delivering interleukin-1 receptor antagonist.
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
BR112014031874A2 (en) method for preparing high concentration stem cells
BRPI0921726B8 (en) method of preparing an implant composition to promote bone growth in a mammal
ES2721180T3 (en) Therapeutic products using fat cells and cell secretions
NZ608734A (en) Bone marrow derived cd271 precursor cells for cardiac repair
WO2011082038A3 (en) Improved reprogramming compositions
TR201911258T4 (en) 3D in vitro biphasic cartilage-bone structure.
CY1118073T1 (en) COMPOSITIONS AND METHODS FOR INCREASING THE TELECOMMUNICATION ACT
MX2013004061A (en) Cyclosporin analogs.
WO2009089110A3 (en) Methods for repair and regeneration of bone marrow
MX2014004994A (en) Cysteamine in the treatment of fibrotic disease.
MX2013004062A (en) Cyclosporin analogs.
EA201490995A1 (en) USE OF FO-TI TO ENHANCE MOBILIZATION AND PROLIFERATION OF STEM CELLS
BR112012016128A2 (en) therapeutic agent (y-39983) for corneal endothelial dysfunction
WO2010123699A3 (en) Compositions, kits and methods for promoting ischemic and diabetic wound healing
WO2014140930A3 (en) Compostions and methods for enhancing the therapeutic potential of stem cells
WO2011013909A3 (en) Composition containing oligo-hyaluronic acid for promoting the stemness of skin cells and for stimulating differentiation
WO2008011133A3 (en) Compositions of late passage mesenchymal stem cells (mscs)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements